The emerging role of cell-free DNA as a molecular marker for cancer management

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and monitoring. However, harnessing the full potential of cfDNA requires (i) the optimization and standardization of preana...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecular detection and quantification 2019-03, Vol.17, p.100087, Article 100087
Main Authors: Bronkhorst, Abel Jacobus, Ungerer, Vida, Holdenrieder, Stefan
Format: Article
Language:English
Subjects:
Biomarker
Cancer
Cell-free DNA
Circulating tumor DNA
Liquid biopsy
Precision oncology
Special Issue on Liquid Biopsy & Biomarkers, Edited by Dr Michael Pfaffl
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and monitoring. However, harnessing the full potential of cfDNA requires (i) the optimization and standardization of preanalytical steps, (ii) refinement of current analysis strategies, and, perhaps most importantly, (iii) significant improvements in our understanding of its origin, physical properties, and dynamics in circulation. The latter knowledge is crucial for interpreting the associations between changes in the baseline characteristics of cfDNA and the clinical manifestations of cancer. In this review we explore recent advancements and highlight the current gaps in our knowledge concerning each point of contact between cfDNA analysis and the different stages of cancer management.
ISSN:2214-7535
2214-7535
DOI:10.1016/j.bdq.2019.100087